ExeVir Bio develops modular llama-derived single-domain antibody (VHH) therapeutics designed to be multi-specific for prophylaxis and treatment of infectious diseases. Its platform aims to generate cross-reactive molecules with dual modes of action and long treatment windows, including candidates that target all four dengue serotypes. The company’s pipeline includes XVR012 (a bi-specific COVID-19 candidate slated for First‑in‑Human studies in 2024), XVR021 for dengue, and XVR031 for pandemic preparedness. ExeVir has progressed candidates from research to clinic rapidly and completed Phase 1a and 1b studies while scaling manufacturing. Financially, ExeVir has received a two-year €1.6M R&D grant from VLAIO and reports cumulative non-dilutive support of €18M from VLAIO, SPW‑Recherche and the European Union; it also completed a €42M Series A and secured a €25M venture debt option from the European Investment Bank. The company is a spin‑out of VIB and is based in Ghent, Belgium. ExeVir Bio is a clinical-stage biotechnology company spun out of VIB in Ghent, Belgium, developing llama-derived VHH (nanobody) therapeutics and multi-specific antibodies targeting infectious diseases. The company’s initial focus is prevention of COVID-19 in immunocompromised patients, where current vaccines and therapies have limitations. Its lead asset, XVR012, is a COVID-19 neutralizing antibody that targets the S1 and S2 regions of the coronavirus. ExeVir is advancing XVR012 toward clinical trials and intends to use the new financing to support that progress. The company is led by CEO Torsten Mummenbrauer and COO Fiona du Monceau. ExeVir has been backed by Fund+ (which led a €42M Series A) and an international consortium, and has received €16.5M in non-dilutive funding from VLAIO, SPW‑Recherche and the European Union. ExeVir leverages a VHH technology platform to generate antiviral therapies that offer broad protection against viral infections, including coronaviruses. The company is a spin‑out from VIB based on the work of Professor Drs Xavier Saelens and Nico Callewaert. Led by CEO Torsten Mummenbrauer, ExeVir's lead compound is XVR011. The company plans to commence a global phase 1b/2 clinical trial of XVR011 and to develop a VHH72‑Fc subcutaneous formulation for COVID‑19 in parallel. ExeVir also intends to accelerate development of its broader infectious‑disease pipeline beyond COVID‑19. Financially, ExeVir closed a US$50M Series A financing to support these programs. ExeVir Bio is a Belgium-based biotech harnessing a llama-derived single-domain antibody platform to generate antiviral therapies providing broad protection against coronaviruses. Its lead candidate, VHH72-Fc, binds a unique epitope on SARS‑CoV‑1 and SARS‑CoV‑2 and has shown neutralization in preclinical studies and in vitro assays. The company says llama-derived antibodies are smaller than human antibodies, allowing them to attach to parts of the virus that would otherwise be inaccessible. Founded by VIB, UCB Ventures and Fund+, ExeVir aims to develop VHH72-Fc for both therapeutic and prophylactic use. The company received a $27M Series A cash infusion to rapidly advance its lead compound into clinical studies by the end of the year. The financing is supported by multiple institutional and governmental investors and will include new investor representatives on ExeVir’s board.

Total raised

$105M

Funding rounds

4

Latest round

Grant

Latest activity

Jun 2023